# US 2012/0231472 A1 · Methods and compositions for diagnosis and prognosis of renal injury and renal failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231472 A1
- Document ID: US20120231472A1
- Status: Published application
- Kind: A1
- Application number: 13/508,362
- Filed: 2010-11-05
- Published: 2012-09-13
- Earliest claimed: 2009-11-07
- Assignees: Astute Medical, Inc.
- Inventors: Joseph Anderberg; Jeff Gray; Paul McPherson; Kevin Nakamura; James Patrick Kampf
- Web page: https://patentgrep.com/patent/US20120231472A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C—C motif chemokine 23, Transmembrane glycoprotein NMB, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

## Claims

### Claim 1

A method for evaluating renal status in a subject, comprising:
obtaining a body fluid sample from a subject selected for evaluation based on a determination that the subject is at risk of a future or current acute renal injury;
performing one or more analyte binding assays configured to detect one or more biomarkers selected from the group consisting of C—C motif chemokine 23, soluble Transmembrane glycoprotein NMB, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 by introducing the body fluid sample obtained from the subject into an assay instrument which, for each analyte binding assay performed, (i) contacts all or a portion of the body fluid sample with a specific binding reagent which specifically binds the biomarker being assayed, (ii) and generates an assay result indicative of binding of the biomarker being assayed to the specific binding reagent;
displaying the assay result(s) generated by the assay instrument in a human-readable form; and
correlating the assay result(s) to the renal status of the subject.

### Claim 2 (depends on 1)

A method according to claim 1, wherein said correlation step comprises correlating the assay result(s) to one or more of risk stratification, diagnosis, staging, prognosis, classifying and monitoring of the renal status of the subject.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

A method according to claim 1, wherein said correlating step comprises assigning a likelihood of one or more future changes in renal status to the subject based on the assay result(s), wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).

### Claim 5

(canceled)

### Claim 6 (depends on 1)

A method according to claim 1, wherein a plurality of assay results are combined using a function that converts the plurality of assay results into a single composite result, and the assay results displayed in human readable form comprise the single composite result.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 4)

A method according to claim 4, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

### Claim 12 (depends on 1)

A method according to claim 1, wherein said correlating step comprises assigning a diagnosis of the occurrence or nonoccurrence of one or more of an injury to renal function, reduced renal function, or ARF to the subject based on the assay result(s).

### Claim at position 13

13-25. (canceled)

### Claim 26 (depends on 4)

A method according to claim 4, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.

### Claim 27 (depends on 1)

A method according to claim 1, wherein the subject is in RIFLE stage 0 or R; wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 72 hours; wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours; wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours; wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours; wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours; wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours; wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours; wherein the subject is in RIFLE stage 0, R, or I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours; or wherein the subject is in RIFLE stage I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

### Claim at position 16

28-36. (canceled)

### Claim 37 (depends on 27)

A method according to claim 27, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 48 hours; wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours; or wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

### Claim at position 18

38-45. (canceled)

### Claim 46 (depends on 27)

A method according to claim 27, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 24 hours; wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours; or wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

### Claim at position 20

47-54. (canceled)

### Claim 55 (depends on 1)

A method according to claim 1, wherein the subject is not in acute renal failure at the time at which the body fluid sample is obtained.

### Claim 56 (depends on 1)

A method according to claim 1, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 57 (depends on 1)

A method according to claim 1, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.

### Claim 58 (depends on 1)

A method according to claim 1, wherein the subject has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 59 (depends on 1)

A method according to claim 1, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 60 (depends on 1)

A method according to claim 1, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 61 (depends on 1)

A method according to claim 1, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.

### Claim 62 (depends on 1)

A method according to claim 1, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 63 (depends on 1)

A method according to claim 1, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours, 48 hours, or 24 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

### Claim at position 30

64-74. (canceled)

### Claim 75 (depends on 1)

A method according to claim 1, wherein the subject has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 76 (depends on 1)

A method according to claim 1, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained.

### Claim 77 (depends on 1)

A method according to claim 1, wherein the subject (i) has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 2 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 78 (depends on 1)

A method according to claim 1, wherein the subject has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 79 (depends on 1)

A method according to claim 1, wherein the subject has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained.

### Claim 80 (depends on 1)

A method according to claim 1, wherein the subject (i) has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

### Claim 81 (depends on 1)

A method according to claim 1, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours 48 hours, or 24 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 12 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

### Claim at position 38

82-89. (canceled)

### Claim 90 (depends on 1)

A method according to claim 1, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

### Claim 91 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

### Claim 92 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

### Claim 93 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 3-fold or greater increase in serum creatinine.

### Claim 94 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

### Claim 95 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 3-fold or greater increase in serum creatinine.

### Claim 96 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

### Claim 97 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 3-fold or greater increase in serum creatinine.

### Claim 98 (depends on 90)

A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

### Claim at position 48

99-108. (canceled)
